Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLCE: Dolutegravir-Lamivudine in Advanced HIV
NCT04880395Phase 4Completed
- Sponsor
- Fundación Huésped
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 4 trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Fundación Huésped. Started May 2021; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04880395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880395.